Liberating Technologies

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Liberating Technologies sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 3 currently recruiting 9 completed early-phase tilt top decile by trial count

Liberating Technologies: 13 sponsored US clinical trials, 3 recruiting.

Liberating Technologies sponsors 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prosthesis User, with 5 trials.

Top-decile sponsor footprint

Liberating Technologies ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

13 total, page 1 of 1

RECRUITING NA

Effects of Myoelectric Channel Count and Targeting for Upper Limb Prosthetic Control

NCT07011420
RECRUITING NA

Caesar Foot Take-Home Validation Testing

NCT07075198
RECRUITING NA

Clinical Outcomes With Non-Powered vs. Powered Prosthetic Knees by K2-level Amputees

NCT06194838
COMPLETED NA

Wireless Prosthetic Control Effectiveness Study

NCT06821412
COMPLETED NA

Clinical Outcomes With Passive MPKs vs. Powered Prosthetic Knees

NCT05267639
COMPLETED NA

Dexterous Partial Hand Prosthesis Outcomes

NCT05038566
TERMINATED NA

Moisture Management Liner At-Home Evaluation

NCT05124873
COMPLETED NA

Moisture Management Liner Effectiveness Study

NCT04427007
COMPLETED NA

Functional Outcomes of Voice Recognition Prosthesis

NCT04595071
COMPLETED NA

Hand Assistive Rehabilitation Orthotic Device Effectiveness Study

NCT04565639
COMPLETED NA

Socket Cooling Effectiveness Take Home Study

NCT04484805
COMPLETED NA

Myoelectric Game Training and Outcomes

NCT04354493
COMPLETED Early Phase 1

EMG-Based Hand-Wrist Control: Study B Mirrored

NCT04692571

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

Prosthesis User 5
Amputation 4
Amputation; Traumatic, Leg: Thigh, Between Hip and Knee 2
Limb; Absence, Congenital, Lower 2
Lower Limb Amputation Above Knee (Injury) 2
Amputation; Traumatic, Leg, Lower 2
Prosthesis 1
Amputation; Traumatic, Arm: Forearm, Between Elbow and Wrist 1
Upper Limb Amputation Below Elbow (Injury) 1
Amputation, Congenital 1

What is open in the Liberating Technologies pipeline

3 recruiting of 13 indexed (23% open); 9 completed (69%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Prosthesis User (5 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Liberating Technologies: open-pipeline peers nationwide

Peers matched on 13 registered trials and 23% open enrollment, not the therapeutic-area sidebar.

Liberating Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1015202530 0%5%10%15%20%25% Total trials Recruiting share Liberating TechnologiesAdaptimmuneAgennixAkili Interactive LabsAlumisClemson UniversityRahul AggarwalSequenomSumitomo Pharma Switzerland
Liberating Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Liberating Technologies sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 23% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Liberating Technologies page

13 registered trials is a research-attention snapshot, not an endorsement of Liberating Technologies or any single study.

  • 3 of Liberating Technologies's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prosthesis User is the condition Liberating Technologies studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prosthesis User trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Liberating Technologies pipeline card: 13 registered trials from official public datasets.Report a data error.